Growth factors and transplant vascular disease

Transplantation Reviews

Volumn 12, Issue 2, 1998, Pages 96-109

  Saito, Satoshi ^a   Lou, Hong ^a   Ramwell, Peter W ^a   Foegh, Marie L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004861502     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(98)80034-7     Document Type: Article

References (130)

1. Libby P, Swansson SJ, Tanaka H, et al: Immunopathology of coronary arteriosclerosis in transplanted heart. J Heart Lung Transplant 1992, 11:S5(suppl 1)
2. Russel PS, Chase CM, Winn HJ, et al: Coronary atherosclerosis in transplanted mouse hearts: Effects of recipient treatment with a monoclonal antibody to interferon gamma. Transplantation 1994, 57:1367
3. Kuwahara M, Jacobson J, Kuwahara M, et al: Coronary artery ultrastrucural changes in cardiac transplant arteriosclerosis in the rabbit. Transplantation 1991, 52:759
4. Billingham ME: Histopathology of graft coronary disease. J Heart Lung Transplant 1992, 11:S38
5. Pucci AM, Forbes RD, Billingham ME: Pathologic features in long-term cardiac allografts. J Heart Transplant 1990, 9:339
6. Haase J, Ozaki Y, Di Mario C, et al: Can intracoronary ultrasound correctly assess the luminal dimensions of coronary artery lesions? A comparison with quantitative angiography. Eur Heart J 1995, 16:112
7. Uretsky BF, Kormos RL, Zerbe TR, et al: Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Lung Transplant 1992, 11:S45
8. Modena FM, Hostetter TH, Salahudeen AK, et al: Progression of kidney disease in chronic renal transplant rejection. Transplantation 1991, 52:239
9. Paul LC, Hayry P, Foegh M, et al: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 1993, 25:2022
10. Isoniemi H, Tikkanen MJ, Ahonen J, et al: Renal allograft immunosuppression. TV: Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transpl Int 1991, 4:130
11. Spector NM, Connolly MA, Garrity ER, Jr: Lung transplant rejection: Obliterative bronchiolitis. Am J Crit Care 1996, 5:366
12. Demetris AJ, Qian SG, Sun H, et al: Liver allograft rejection: An overview of morphologic findings. Am J Surg Pathol 1990, 1:49
13. Wiesner RH, Ludwig J, van Hoek B, et al: Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991, 14:721
14. Secchi A, Di Carlo V, Pozza G: Pancreas and islet transplantation: Current progresses, problems and perspectives. Horm Metab Res 1997, 29:1
15. Almond PS, Matas A, Gillingham K, et al: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993, 55:752
16. Lemstrom KB, Raisanen-Sokolowski AK, Hayry PJ, et al: Triple drug immunosuppression significantly reduces aortic allograft arteriosclerosis in the rat. Arterioscler Thromb Vasc Biol 1996, 16:553
17. Forbes RD, Zheng SX, Gomersall M, et al: Irreversible chronic vascular rejection occurs only after development of advanced allograft vasculopathy: A comparative study of a rat cardiac allograft model using a retransplantation protocol. Transplantation 1997, 63:743
18. Pober JS, Collins T, Gimbrone MA Jr, et al: Inducible expression of class II major histocompatibility complex antigens, the immunogenecity of vascular antigens, and the immunogenecity of vascular endothelium. Transplantation 1986, 11:9
19. Amaildi I, Reith W, Berte C, et al: Induction of HLA genes by IFN-γ is transcriptional and requires transacting protein. J Immunol 1989, 142:999
20. Hart PH, Bonder CS, Jones CA, et al: Control of major histocompatibility complex class II expression on human monocytes by interleukin 4: Regulatory effect of lipopolysaccharide. Immunology 1996, 89:599
21. +) T-cell lines. J Exp Med 1997, 185:1769
22. Reith W, Steimle V, Mach B: Molecular defects in the bare lymphocytes syndrome and regulation of MHC class II genes. Immunol Today 1995, 16:539
23. Glimcher LH, Kara CJ: Sequences and factors: A guide to MHC class II transcription. Annu Rev Immunol 1992, 10:13
24. Dong C, Wilson JE, Winters GL, et al: Human transplant coronary artery disease: Pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996, 74:921
25. Szabolcs M, Michler RE, Yang X, et al: Apoptosis of cardiac myocytes during cardiac allograft rejection: Relation to induction of nitric oxide synthase. Circulation 1996, 94:1665
26. Russel ME, Wallace AF, Wyner LR, et al: Up-regulation and modulation of inducible nitric oxide synthetase in rat cardiac allograft with chronic rejection and transplant arteriosclerosis. Circulation 1995, 92:457
27. von Willebrand E, Krogerus L, Salmela K, et al: Expression of adhesion molecules and their ligands in acute rejection of human kidney allografts. Transplant Proc 1995, 27:917
28. Hines KL, Kulkarni AB, McCarthy JB, et al: Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci USA 1994, 91:5187
29. Labarrere CA, Pitts D, Nelson DR, et al: Coronary artery disease in cardiac allografts: Association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc 1995, 27:1939
30. Ardehali A, Laks H, Drinkwater DC, et al: Vascular cell adhesion molecule 1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation 1995, 92:450
31. Rubin LA, Nelson DL: The soluble interleukin 2 receptor: Biology, function, and clinical application. Ann Intern Med 1995, 113:619
32. Giraudo E, Arese M, Toniatti C, et al: IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. J Immunol 1996, 157:2618
33. Clausell N, Molossi S, Sett S, et al: In vivo blockade of tumor necrosis factor alpha in cholesterol fed rabbits after cardiac transplantation inhibits acute coronary artery neointimal formation. Circulation 1994, 89:2768
34. Raisanen SA, Hayry P: Chronic allograft arteriosclerosis: Contributing factors and molecular mechanisms in the light of experimental studies. Transpl Immunol 1996, 4:91
35. Aziz S, McDonald O, Gohra H: Transplant arterial vasculopathy: Evidence for a dual pattern of endothelial injury and the source of smooth muscle cells in lesions of intimal hyperplasia. J Heart and Lung Transplant 1995, 14:S123
36. Ross C: Somatogenic hormones and insulin-like growth factor I: Stimulation of proliferation and immune function. Endocr Rev 1987, 18:157
37. Hosenpud JD, Everett JP, Morris TE, et al: Cardiac allograft vasculopathy: Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium. Circulation 1995, 92:205
38. Chow LH, Huh S, Jiang J, et al: Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 1996, 94:3079
39. Akalin E, Chandraker A, Russell ME, et al: CD28-B7 T cell costimulatory blockade by CTLA4 Ig in the rat renal allograft model: Inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 1996, 62:1942
40. Russell PS, Chase CM, Winn HJ, et al: Coronary atherosclerosis in transplanted mouse hearts. I: Time course and immunogenetic and immunopathological considerations. Am J Pathol 1994, 144:260
41. Frystyk J, Skjaerbaek C, Alexander N, et al: Lanreotide reduces serum free and total insulin-like growth factor I after angioplasty. Circulation 1996, 91:2465
42. Gronbaek H, Skjaerbaek C, Nielsen B, et al: Growth hormone and insulin-like growth factor I: A suggested role in renal transplantation and graft vessel disease. Transplant Proc 1995, 27:2133
43. Wolthers T, Grofte T, Flyvbjerg A, et al: Dose-dependent stimulation of insulin-like growth factor-binding protein 1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab 1994, 78:141
44. Frystyk J, Hussain M, Skjaerbaek C, et al: Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. Am J Physiol 1997, 273:E507
45. Orskov H, Gronbak H, Skjarbaek C, et al: Possible effects and mechanism of actions of IGF-I in development of diabetic complications, in Sakamoto N, Alberti KGMM, Ilotta N (eds): Pathogenesis and treatment of NIDDM and its related problems. Exerpta Medica, 1994
46. Stiles CD, Capone GT, Scher CD, et al: Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 1979, 76:1279
47. Grant M, Wargovich G, Ellis E, et al: Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth cells. Circulation 1994, 89:1511
48. Lou H, Zhao Y, Delafontaine P, et al: Estrogen effects on insulin growth factor I (IGF-I) induced cell proliferation and IGF-I expression in native and allograft vessels. Circulation 1997, 96:927
49. Yamamoto M, Yamamoto K: Growth regulation in primary culture of rabbit arterial smooth muscle cells by platelet-derived growth factor, insulin-like growth factor I, and epidermal growth factor. Exp Cell Res 1994, 212:62
50. Delafontaine P, Meng XP, Du J: Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate oligonucleotides: Effects on growth and evidence that genes targeting at the ATG site increase receptor expression. J Biol Chem 1995, 270:1995
51. Motomura N, Lou H, Maurice P, et al: Acceleration of arteriosclerosis of the rat aorta allograft by insulin growth factor I. Transplantation 1997, 63:932
52. Clark R, Strasser J, McCabe S, et al: Insulin-like growth factor I stimulation of lymphopoiesis. J Clin Invest 1993, 92:510
53. Saito S, Motomura N, Lou H, et al: Specific effects of estrogen on growth factor and major histocompatibility complex class II antigen expression in aortic allograft. J Thorac Cardiovasc Surg 1997, 114:803
54. Lou H, Kodama T, Zhao YJ, et al: Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. Circulation 1996, 94:3355
55. Ballard FJ, Wallace JC, Francis GL, et al: Des(1-3)IGF-I: A truncated form of insulin-like growth factor I. Int J Biochem Cell Biol 1996, 28:1085
56. Adesanya OO, Zhou J, Bondy CA: Cellular localization and sex steroid regulation of insulin-like growth factor binding protein messenger ribonucleic acids in the primate myometrium. J Clin Endocrinol Metab 1996, 81:2495
57. Howell M, Frystyk J, Orskov H, et al: Lanreotide, a somatostatin analogue, reduces insulin-like growth factor I accumulation in proliferating aortic tissue in rabbit in vivo: A preliminary study. Eur J Endocrinol 1994, 130:422
58. More SR, Brack MJ, Underwood MJ, et al: Growth factor persistence after vessel voll injury in a rabbit angioplasty model. Am J Cardiol 1994, 73:1031
59. Cercek B, Fishbein MC, Forrester JS, et al: Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 1990, 66:1755
60. Ross R, Raines EW, Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 1986, 46:155
61. Lemstrom K, Koskinen P, Hayry P: Molecular mechanisms of chronic renal allograft rejection. Kidney Int Suppl 1995, 52:S2
62. Lemstrom KB, Koskinen PK: Expression and localization of platelet-derived growth factor ligand and receptor protein during acute and chronic rejection of rat cardiac allograft. Circulation 1997, 96:1240
63. Zhao XM, Yeoh TK, Frist WH, et al: Induction of acidic fibroblast growth factor and full-length platelet-derived growth factor expression in human cardiac allografts: Analysis by PCR, in situ hybridization, and immunohistochemistry. Circulation 1994, 90:677
64. Ross R, Masuda J, Raines EW, et al: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990, 248:1009
65. Shaddy RE, Hansen JC, Cowley CG: Effects of T cells on platelet-derived growth factor-like protein secretion from endothelial cells. J Heart Lung Transplant 1992, 11:48
66. Raisanen SA, Mennander A, Ustinov J, et al: Chronic rejection in rat aortic allograft: Mechanism of angiopeptin (BLM 23014C) inhibition on vascular smooth muscle cell proliferation in chronic rejection. Transplant Proc 1993, 25:944
67. Hayry P: Chronic allograft rejection: An update. Clin Transplant 1994, 26:3159
68. Raisanen SA, Tilly KM, Ustinov J, et al: Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb Vasc Biol 1994, 14:2032
69. Gospodarowicz D, Neufeld G, Schweigerer L: Fibroblast growth factor: Structural and biological properties. J Cell Physiol 1987, 5:15 (suppl)
70. Cuevas P, Carceller F, Cuevas B, et al: A nonmitogenic form of acidic fibroblast growth factor reduces neutrophil infiltration in rat ischemic reperfused heart. Eur J Med Res 1997, 2:139
71. Dougglas AVL, Baird LA, Majack RA, et al: Role of basic fibrobrast growth factor in vascular lesion formation. Circ Res 1991, 68:106
72. Willson SE, Lloyd SA: Epidermal growth factor and its receptor, basic fibrobrast growth factors, transforming growth factor beta 1, and interleukin Iα mRNA production in human corneal endothelial cells. Invest Opthalmol Vis Sci 1991, 32:2747
73. Ettenson DS, Gotlieb AI: Basic fibroblast growth factor is a signal for the initiation of centrosome redistribution to the front of migrating endothelial cells at the edge of an in vitro wound. Arterioscler Thromb Vasc Biol 1995, 15:515
74. Lindner V, Lappi DA, Baird A, et al: Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991, 68:106
75. Reape TJ, Kankzler JM, Ward JP, et al: IGF-I increases bFGF-induced mitogenesis and up-regulates FGFR-1 in rabbit vascular smooth muscle cells. Am J Physiol 1996, 270:1141
76. Stoscheck CM, King LE, Jr: Functional and structural characteristics of EGF and its receptor and their relationship to transforming proteins. J Cell Biochem 1986, 31:135
77. Crowley ST, Ray CJ, Nawaz D, et al: Multiple growth factors are released from mechanically injured vascular smooth muscle cells. Am J Physiol 1995, 269:H1641
78. Toubeau G, Nonclercq D, Zanen J, et al: Renal tissue expression of EGF and EGF receptor after ischaemic tubular injury: An immunohistochemical study. Exp Nephrol 1994, 2:229
79. Stouffer GA, Owens GK: TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest 1994, 93:2018
80. Wahl SM: Transforming growth factor beta (TGF-β) in inflammation: A cause and a cure. J Clin Immunol 1992, 12:61
81. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993, 362:801
82. Newby AC, George SJ: Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. Curr Opin Cardiol 1996, 11:574
83. Geiser AG, Letterio JJ, Kulkarni AB, et al: Transforming growth factor beta 1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: Aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc Natl Acad Sci USA 1993, 90:9944
84. Torry RJ, Labarrere CA, Torry DS, et al: Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 1995, 60:1451
85. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996, 7:259
86. Grone HJ, Simon M, Grone EF: Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995, 177:259
87. Johnson MR: Transplant coronary disease: Nonimmunologic risk factors. J Heart Lung Transplant 1992, 11:S124
88. Escobar A, Ventura HO, Stapleton DD, et al: Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1991, 74:1012
89. Gao SZ, Hunt SA, Schroeder JS, et al: Early development of accelerated graft coronary artery disease: Risk factors and course. J Am Coll Cardiol 1996, 28:673
90. Kemna MS, Valantine HA, Hunt SA, et al: Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 1991, 128:68
91. Valantine HA: Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995, 14:S234
92. Meiser BM, Wenke K, Thiery J, et al: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993, 25:2077
93. Motomura N, Saito S, Foegh ML: HMG-CoA reductase inhibitors in organ transplantation. J Nephrol 1997, 10:68
94. Grattan MT, Moreno-Cabral CE, Starnes VA, et al: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561
95. Fujinami RS, Nelson JA, Walker L, et al: Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: A means for graft rejection and immunosuppression. J Virol 1988, 62:100
96. Speir E, Modali R, Huang ES, et al: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265:391
97. Day JD, Rayburn BK, Gaudin PB, et al: Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995, 14:S142
98. Reichart B, Meiser BM, Wenke K, et al: What is the role of lipid lowering therapy in heart-allograft failure? Kidney Int Suppl 1995, 52:525
99. Meiser BM, Billingham ME, Morris RE: Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 1991, 338:1297
100. Arai S, Teramoto S, Senoo Y: The impact of FK506 on graft coronary disease of rat cardiac allograft: A comparison with cyclosporine. J Heart Lung Transplant 1992, 11:757
101. Leszczysnki D, Zhao Y, Yeagley TJ, et al: Direct and endothelial cell-mediated effect of cyclosporin A on the proliferation of rat smooth muscle cells in vitro. Am J Pathol 1993, 142:149
102. Pham SM, Kormos RL, Hattler BG, et al: A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996, 111:764
103. Azuma H, Binder J, Heemann U, et al: Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995, 59:460
104. Gregory CR, Huang X, Pratt RE, et al: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995, 59:655
105. Raisanen SA, Vuoristo P, Myllarniemi M, et al: Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995, 3:342
106. Weis M, von Sheidt W: Cardiac allograft vasculopathy: A review. Circulation 1997, 96:2069
107. Poon M, Marx SO, Gallo R, et al: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996, 98:2277
108. Servant MJ, Giasson E, Meloche S: Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J Biol Chem 1996, 271:16047
109. Suthanthiran M, Morris RE, Strom TB: Immunosuppressants: Cellular and molecular mechanisms of action. Am J Kidney Dis 1996, 28:159
110. Voisard R, Seltzer U, Baur R, et al: Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994, 43:257
111. Nauck M, Roth M, Tamm M, et al: Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down-regulated by corticosteroids. Am J Respir Cell Mol Biol 1997, 16:398
112. Kofnek SD: Postmenopausal hormone replacement therapy and cardiovascular risk reduction. Drugs 1994, 47:16 (suppl 2)
113. Foegh ML, Asotra S, Howell MH, et al: Estrasdiol inhibition of arterial neointimal hyperplasia after balloon injury. J Vasc Surg 1993, 19:722
114. Cheng LP, Kuwahara M, Jacobsson J, et al: Inhibition of myointimal hyperpalsia and macrophage infiltration by estradiol in aorta allograft. Transplantation 1991, 52:967
115. Lou H, Ramwell PW, Foegh ML: Estradiol down-regulates insulin-like growth factor I receptor (IGF-IR) mRNA expression in aortic smooth cells. Circulation 1996, 94:1152 (suppl)
116. Saito S, Foegh ML, Motomura N, et al: Estradiol inhibits allograft inducible major histocompatibility (MHC) class II antigen expression and transplant arteriosclerosis in the absence of immunosuppression, (submitted)
117. Seiki K, Sakabe K: Sex hormones and the thymus in relation to thymocyte proliferation and maturation. Arch Histol Cytol 1997, 60:29
118. Fox FS, Bond BL, Parslow TG: Estrogen regulates the IFN-γ promotor. J Immunol 1991, 146:4362
119. Suzuki A, Mizuno K, Okada M, et al: Effects of 17 beta estradiol and progesterone on growth factor induced proliferation and migration in human female aortic smooth muscle cell in vitro. Cardiovasc Res 1996, 32:516
120. Shanker G, Sorci TM, Adams MR: Estrogen modulates the inducible expression of platelete-derived growth factor mRNA by monocytes/macrophage. Life Sci 1995, 56:499
121. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1991, 135:2814
122. Foegh ML, Ramwell PW: Angiopeptin: Experimental and clinical studies of inhibition of myointimal proliferation. Kidney Int Suppl 1995, 48(Suppl 52):518
123. Motomura N, Foegh ML: Angiopeptin: An immunological review. Transpl Immunol 1996, 4:99
124. Light JT, Bellan JA, Chen IL, et al: Angiopeptin enhances acetylcholine-induced relaxation and inhibits intimal hyperplasia after vascular injury. AmJ Physiol 1993, 265:H1265
125. Wahlers T, Mugge A, Oppelt P, et al: Coronary vasculopathy following cardiac transplantation and cyclosporine immunosuppression: Preventive treatment with angiopeptin, a somatostatin analog. Transplant Proc 1994, 26:2741
126. Eriksen UH, Amtorp O, Bagger JP, et al: Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 1995, 130:1
127. Emanuelsson H, Beatt KJ, Bagger JP, et al: Long-term effects of angiopeptin treatment in coronary angioplasty: Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation 1995, 91: 1689
128. Shimokado K, Umezawa K, Ogata J: Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Exp Cell Res 1995, 220:266
129. Shimokado K, Yokota T, Umezawa K, et al: Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1991, 14:973
130. Kuiper GG, Carlsson B, Grandien K, et al: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863